Skip to main content
PLX
NYSE Life Sciences

Protalix 10-Q: $26.1M Nine-Month Profit, $48.5M Cash, No Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.581
Mkt Cap
$207.069M
52W Low
$1.65
52W High
$3.19
52W Position info
56% above low
Off High info
19% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PLX sits 56% above its 52-week low of $1.65.

Summary

Protalix's Q3 10-Q shows nine-month net income of $26.1M (boosted by a $25.0M Chiesi milestone), $48.5M of cash and deposits with no debt, and continued modest ATM selling — 1.6M shares for $4.3M in Q3 plus 1.8M shares for $4.9M after quarter-end.


Key Events · Earnings and Guidance · PLX

  • Nine-Month Profit of $26.1M

    Net income was $26,055K for the nine months ended September 30, 2026 versus a $(1,100)K loss a year earlier; Q3 alone earned $3,961K ($0.05 per diluted share) on $21,925K of revenue.

  • Revenue Jump on Chiesi Milestone

    Nine-month revenue reached $75,571K versus $43,622K, including $26,490K of license and R&D revenue that contains the $25.0M E4W-dosage milestone received March 31, 2026.

  • $48.5M Cash, No Debt

    Cash and cash equivalents of $22,035K plus short-term bank deposits of $26,503K totaled $48.5M at September 30, 2026; management states this funds at least 12 months of operations.

  • ATM Still Dripping Shares

    1,613,992 shares were sold under the Sales Agreement in Q3 for ~$4.3M gross ($0.1M costs), and a further 1,798,325 shares for ~$4.9M gross after quarter-end; ~$11.3M remains available.


Analysis · PLX · Life Sciences

The 10-Q puts hard numbers behind this morning's 8-K headline. Nine-month net income of $26.1M versus a $1.1M loss a year ago is driven largely by the one-time $25.0M Chiesi milestone booked in Q1, so the underlying run-rate is thinner than the headline: Q3 alone earned $4.0M on $21.9M of revenue. The balance sheet is the real story — $48.5M in cash and short-term deposits with no debt and no warrants, which management says funds at least 12 months of operations. Against that, the company is still drip-selling stock: 1.6M shares for $4.3M in Q3 and another 1.8M shares for $4.9M after quarter-end, leaving $11.3M on the ATM. R&D spend rose 55% in Q3 to $6.9M as the PRX-115 gout study ramps, partly offset by a $1.0M Israeli R&D grant.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PLX was trading at $2.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $207.1M. The 52-week trading range was $1.65 to $3.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLX - Latest Insights

PLX
Nov 10, 2026, 6:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.71
Real-time Price: $2.59 info
Change: -$0.120 (-4%) info
Market Cap: $207.069M info